Back Avantium announces 2019 results: advances its lead technologies towards commercialisation AMSTERDAM, 25 March 2020, 07:00 CET Tom van Aken, CEO of Avantium said: “2019 was a pivotal year for Avantium, in which we continued to focus on our commitment to becoming a...
Back Avantium enters the Euronext Amsterdam SmallCap Index (AScX) AMSTERDAM, 10March2020, 20:45CET–Avantium announces that it has been promoted tothe Euronext Amsterdam SmallCap Index (AScX), following the quarterly review by Euronext.The AScX index consists of the 25...
Back Avantium sells bioaromatics patent portfolio to TNO AMSTERDAM, 24 February 2020, 07:00 CET – Avantium has sold its bioaromatics patent portfolio to The Netherlands Organization for Applied Scientific Research, TNO. The sale includes both patents and know-how for...
Back Michelle Jou nominated as a new member of Avantium’s Supervisory Board AMSTERDAM, 15 January 2020, 08:30 CET – Avantium, a leading technology company in renewable chemistry, announces that Michelle Jou has been nominated for appointment to its Supervisory Board...
AMSTERDAM, 08 January 2020, 07:00 CET – Avantium, a leading technology company in renewable chemistry, announces today that its wholly owned subsidiary, Avantium Renewable Polymers, has signed a letter of intent to locate its new flagship plant at Chemie Park...
AMSTERDAM, 23 December 2019, 07:00 CET – Avantium, a leading technology company in renewable chemistry, announced today the appointment of Bart Welten as Chief Financial Officer (CFO). Mr. Welten will join Avantium in January 2020. The Supervisory Board proposes to...
Mr Welten will bring 30 years in finance to Avantium and has extensive experience in the chemical and life-sciences industries. He most recently served as the CFO of Centrient Pharmaceuticals (formerly the joint-venture of DSM and Sinochem) in Singapore. Before he left Centrient, he managed the sale of the company to Bain Capital. Prior to this, Mr Welten held the position of CFO of DSM Resins and DSM Anti-Infectives. He holds a law degree from Leiden University (Netherlands) and an MBA from Boston College (USA).
Edwin Moses (chairman) joined the Supervisory Board of the Company in December 2019.
Edwin Moses is a serial entrepreneur and value creator in European life science companies. He has expertise in high value service provision to the pharmaceutical industry and in drug discovery and development. His primary focus is on high growth businesses and change management. Mr. Moses has 25 years of Board level experience in more than 10 companies, mostly as Chairman.
Edwin Moses is Chairman of the Supervisory Board and member of the Audit Committee.
